PERK Loss Sensitizes Colorectal Cancer to Ferroptosis via SLC7A11 Downregulation

Study Background and Research Question

Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has emerged as a targetable vulnerability in therapy-resistant cancers. Colorectal cancer (CRC), which ranks among the most prevalent and deadly malignancies worldwide, often develops resistance to conventional therapies by evading apoptosis—a hallmark of cancer progression. Recent attention has focused on manipulating non-apoptotic cell death pathways, such as ferroptosis, to overcome drug resistance and limit tumor growth. The unfolded protein response (UPR) and endoplasmic reticulum (ER) stress are increasingly recognized as modulators of cancer cell survival and therapy resistance. However, the intersection between UPR signaling, ferroptosis sensitivity, and the cystine/glutamate antiporter SLC7A11 (System Xc−) in CRC remains incompletely understood. The central research question addressed in the reference study is: How does the loss of PERK, a key UPR sensor, influence ferroptosis susceptibility and tumor growth in colorectal cancer?

Key Innovation from the Reference Study

The principal innovation of this work lies in uncovering the mechanistic link between PERK (protein kinase RNA-like ER kinase) activity and ferroptosis regulation in CRC. Specifically, the study demonstrates that PERK loss downregulates SLC7A11 expression, thereby depleting intracellular glutathione (GSH) and sensitizing cancer cells to ferroptosis. This establishes PERK as a negative regulator of ferroptosis, where its inhibition primes therapy-resistant CRC cells for iron-dependent, lipid peroxidation-mediated cell death. The work further shows that PERK and SLC7A11 are positively correlated in patient CRC samples and transcriptomic datasets, emphasizing the clinical relevance of this pathway. The study thereby highlights the potential of modulating ER stress responses to enhance ferroptosis-based therapeutic strategies against apoptosis-resistant malignancies.

Methods and Experimental Design Insights

The research employed a multifaceted approach that integrated cell culture, genetic manipulation, pharmacological inhibition, and in vivo tumor models:

• Human CRC cell lines were treated with RSL3, a potent glutathione peroxidase 4 (GPX4) inhibitor, to induce ferroptosis and monitor UPR pathway activation.
• PERK function was selectively inhibited using both small-molecule inhibitors and genetic knockdown, enabling dissection of its specific role versus other UPR arms (ATF6, IRE1α).
• Chromatin immunoprecipitation (ChIP) was performed to assess ATF4 recruitment to the SLC7A11 promoter, clarifying the transcriptional control exerted by PERK signaling.
• Lipid peroxidation, GSH levels, and cell viability were quantified to establish the biochemical hallmarks of ferroptosis.
• Orthotopic and subcutaneous CRC mouse models were used to evaluate the in vivo consequences of PERK inhibition on tumor growth and ferroptosis in situ.
• Analysis of The Cancer Genome Atlas (TCGA) and patient-derived CRC samples correlated PERK and SLC7A11 expression with clinical parameters.

This comprehensive design enabled the authors to link molecular, cellular, and organismal evidence for the PERK–SLC7A11–ferroptosis axis in CRC.

Core Findings and Why They Matter

The study’s findings reveal several key points:

• RSL3 Induces Both Ferroptosis and UPR: Treatment with RSL3, a GPX4 inhibitor, not only triggers ferroptosis but also activates all three canonical UPR arms (PERK, ATF6, IRE1α) in CRC cells, indicating crosstalk between oxidative stress and ER stress pathways (reference study).
• PERK Is Selectively Critical for Ferroptosis Sensitivity: Inhibition or knockdown of PERK, but not ATF6 or IRE1α, abrogates ATF4-mediated transcription of SLC7A11, resulting in reduced cystine uptake, GSH depletion, and heightened lipid peroxidation—hallmarks of ferroptosis.
• PERK Loss Primes Tumors for Ferroptotic Death: In vivo, PERK inhibition led to a significant reduction in tumor volume, with increased markers of ferroptotic cell death in CRC xenografts, establishing PERK as a resistance factor against ferroptosis-mediated tumor suppression.
• Clinical Relevance: TCGA data and patient specimens show a positive correlation between PERK and SLC7A11 expression, suggesting that this regulatory axis is operational in human CRC and may predict ferroptosis susceptibility.

These results matter because they position the PERK–SLC7A11 pathway as a tractable target for inducing ferroptosis and overcoming therapy resistance in colorectal cancer—a critical unmet need in oncology.

Comparison with Existing Internal Articles

Several internal resources contextualize the present findings within the broader landscape of ferroptosis research:

• "RSL3: The Leading GPX4 Inhibitor for Precision Ferroptosis" and "RSL3: GPX4 Inhibitor for Ferroptosis Induction in Cancer" provide detailed protocols and applications of RSL3 in both in vitro and in vivo models, confirming its central role as a glutathione peroxidase 4 inhibitor and ferroptosis inducer in cancer research. These articles reinforce RSL3’s reliability for dissecting redox-dependent cell death mechanisms, as utilized in the current study.
• "RSL3 and the Final Frontier: Ferroptosis Execution in Cancer" expands on the molecular execution phase of ferroptosis, complementing the mechanistic insights into how upstream factors like PERK modulate susceptibility to lipid peroxidation-driven cell death.
• The present study’s focus on the PERK–SLC7A11 axis adds a new regulatory dimension to the established roles of GPX4 inhibition and oxidative stress, providing a framework for future combination strategies (e.g., targeting both ER stress and redox pathways).

Limitations and Transferability

While the study robustly demonstrates the importance of PERK in ferroptosis regulation, several limitations should be considered:

• Cancer Type Specificity: The experiments are focused on colorectal cancer models; the generalizability to other cancer types requires further validation.
• UPR Complexity: Although PERK’s role is highlighted, the interconnectedness of UPR signaling means compensatory mechanisms might emerge in different tumor contexts.
• In Vivo Modeling: While mouse xenografts provide important in situ evidence, the translation to patient therapy will need careful consideration of tumor heterogeneity and systemic effects.
• Therapeutic Targeting Risks: PERK has roles in normal tissues, so long-term or systemic inhibition could pose toxicity risks that need to be addressed in preclinical development.

Protocol Parameters

• RSL3 dosing in vitro: Commonly used at low nanomolar concentrations (e.g., 100–500 nM) to induce ferroptosis, with cell viability and lipid peroxidation monitored after 12–24 hours of exposure (internal resource).
• PERK inhibition: Pharmacological inhibitors or siRNA-mediated knockdown are used to dissect pathway specificity; duration typically 24–48 hours prior to ferroptosis induction.
• In vivo RSL3 administration: Subcutaneous injection at 100 mg/kg twice weekly has been shown to reduce tumor burden in mouse models, with careful monitoring for toxicity as described in the product dossier.
• GSH and lipid peroxidation assays: Employ commercial kits or HPLC-based quantification to assess oxidative stress and ferroptotic progression.

Research Support Resources

Researchers aiming to replicate or extend these findings can use the (1S,3R)-RSL3 glutathione peroxidase 4 inhibitor (SKU B6095) as a validated tool for inducing ferroptosis and probing GPX4-dependent redox dynamics in cancer models. This reagent supports workflows involving oxidative stress and lipid peroxidation modulation, and is widely referenced in both this and related studies. For detailed guidance on RSL3 use, refer to the cited internal resources and the product technical documentation from APExBIO.